


# PRODUCT INFORMATION



## Halofuginone (hydrochloride)

Item No. 13370

**CAS Registry No.:** 1217623-74-9  
**Formal Name:** 7-bromo-6-chloro-3-[[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4(3H)-quinazolinone, monohydrochloride  
**MF:** C<sub>16</sub>H<sub>17</sub>BrClN<sub>3</sub>O<sub>3</sub> • HCl  
**FW:** 451.1  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 242, 274, 314, 327 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Halofuginone (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the halofuginone (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Halofuginone (hydrochloride) is soluble in DMSO. It is also soluble in water. We do not recommend storing the aqueous solution for more than one day.

### Description

Halofuginone is a halogenated derivative of febrifugine, a natural quinazolinone-containing compound found in the Chinese herb *D. febrifuga*.<sup>1</sup> It has antimalarial and anticoccidial actions.<sup>1</sup> In mammals, halofuginone at 10 ng/ml down-regulates Smad3, blocking TGF-β signaling and preventing both the differentiation of fibroblasts to myofibroblasts and the transitioning of epithelial cells to mesenchymal cells.<sup>1,2</sup> Through this action, halofuginone blocks fibrosis and tumor progression in a variety of different models.<sup>1,3</sup> This compound also competitively inhibits prolyl-tRNA synthetase (K<sub>i</sub> = 18.3 nM), activating the amino acid starvation response.<sup>4,5</sup> This prevents the differentiation of T<sub>H</sub>17 cells, blunting an autoimmune response.<sup>5</sup>

### References

- McLaughlin, N.P., Evans, P., and Pines, M. The chemistry and biology of febrifugine and halofuginone. *Bioorg. Med. Chem.* **22(7)**, 1993-2004 (2014).
- Nelson, E.F., Huang, C.W., Ewel, J.M., et al. Halofuginone down-regulates Smad3 expression and inhibits the TGFβ-induced expression of fibrotic markers in human corneal fibroblasts. *Mol. Vis.* **18**, 479-487 (2012).
- Pines, M., Snyder, D., Yarkoni, S., et al. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. *Biol. Blood Marrow Transplant.* **9(7)**, 417-425 (2003).
- Keller, T.L., Zocco, D., Sundrud, M.S., et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. *Nat. Chem. Biol.* **8(3)**, 311-317 (2012).
- Sundrud, M.S., Koralov, S.B., Feuerer, M., et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. *Science* **324(5932)**, 1334-1338 (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM